|Day Low/High||38.78 / 39.34|
|52 Wk Low/High||36.00 / 46.22|
AT&T and Time Warner kicked off a hearing to defend their $84.5 billion merger. AT&T is no stranger to legal battles and anti-trust battles.
The medical device giant files a suit against Alere in the Delaware Court of Chancery hoping to walk away from their $7.9 billion merger agreement.
ALERE HAS LOST SIGNIFICANT VALUE DUE TO NUMEROUS DAMAGING BUSINESS DEVELOPMENTS THAT OCCURRED FOLLOWING THE MERGER AGREEMENT
Both companies have a track record of raising dividends in December.
Here are Tuesday's top research calls, including upgrades for Pandora and United Continental, and a downgrade for Abbott Labs.
- FOUR ADVOCATE HEALTH CARE HOSPITALS FOLLOWED MORE THAN 1,200 ADULTS AT-RISK OF MALNUTRITION DURING THEIR STAY
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ARII, BPI, CHS, EMXX, GCO, GVP, HAYN, HEES, SMTC, UEPS, XNCR Downgrades: ABT, ACHC, ARL, ARRS, EVK, FSI, NTWK, PIH, WUBA Initiations: PXS Read on to get TheStreet Quant Ratings' detailed report:
In a record year for acquisitions, 18 companies from across the spectrum were singled out by M&A professionals for doing deals that got results.
- DESIGNED TO BE THE WORLD'S EASIEST-TO-USE WITH-PATIENT TESTING DEVICE
Horizon Pharma is a 'giant headache,' says Jim Cramer; Abbot Labs is OK long term.
Holiday-shortened week holds a feast of earnings reports, says Jim Cramer.
European Union regulators are expected to approve Abbott Laboratories' $33 billion acquisition of St. Jude Medical.
- Japan approval makes first-of-its-kind medical device available to people in Japan with coronary artery disease who prefer an alternative to a permanent metallic implant
Abbott wants more information from Alere, as promised under their pending $7.9 billion agreement.
TOP SCIENTIST: ABBOTT'S INNOVATION MISSION APPEALS TO 'HEARTS AND MINDS' OF SCIENTISTS
Levels of FIVE immune markers were nearly identical in breastfed babies and babies fed formula with 2'-FL Human milk oligosaccharide
The medical devices company is likely to stick to small- to mid- sized M&A unless it finds itself the target.
Look for ABT's declining trend to continue a while longer.
Doug Kass shares his thoughts on 'stuck' markets and on differing risk appetites and timeframes.
St. Jude shares deserve to be higher ahead of the merger with Abbott Labs. Here's why.
Shares of the medical-device giant were climbing after unveiling strong earnings.
Political pressure is weighing on drug and medical device stocks including Abbott Labs and St. Jude, says Jim Cramer.
Miles White also reiterated that Abbott Laboratories has no plans to divest of its diabetes business. He still believes in Alere over the long term.
The medical device maker responded to allegations that its devices could be hacked during its third quarter earnings call.